Heat Biologics Inc HTBX shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.
Heat Biologics is a U.S.-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates.
Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96.
Heat Biologics shares were trading up 2.88% at 77 cents on Monday. The stock has a 52-week high of $1.26 and a 52-week low of 20 cents.
Related Links:
Heat Biologics Shares React Amid Circulation Of PatentScope Doc
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
